Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 301–400 of 618
2‐Sulfonylpyrimidines Target the Kinesin HSET via Cysteine Alkylation
Förster, T., Shang, E., Shimizu, K., Sanada, E., Schölermann, B., Huebecker, M., Hahne, G., López‐Alberca, M. P., Janning, P., Watanabe, N., et al. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900586 · Cited by 12
Zhao, Y., Zhao, X., Duan, L., Hou, R., Gu, Y., Liu, Z., Chen, J., Wu, F., Yang, L., Le, X. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02076 · Cited by 11
Ngo, H., Wen, Y. W., Pisupati, S., Huang, W., & Mandlekar, S. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3390 · Cited by 15
Dai, P., Ma, Z., Xie, K., Li, Y., Zhang, Y., Li, C., Sun, Y., Gu, Y., Xia, Q., & Zhang, W. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c09156 · Cited by 12
Ouyang, X., Chai, X., Huang, L., Chen, Y., Li, S., Huang, W., Li, Y.-F., Ding, K., Liu, T., Tan, Y., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202504813 · Cited by 11
Wang, Z., Wang, X., Li, Y., Li, P., Huang, S., Chen, P., Tang, G., Ding, X., Zhang, Z., Zhang, Z., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510763 · Cited by 14
Lv, Q., Zhang, Y., Wang, J., Lin, W., Xie, Y., Yang, H., Yin, X., Zhu, Z., Cui, Y., Hu, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70367 · Cited by 11
Chemically targeting the redox switch in AP1 transcription factor ΔFOSB
Kumar, A., Aglyamova, G. V., Yim, Y. Y., Bailey, A. O., Lynch, H. M., Powell, R. T., Nguyen, N. D., Rosenthal, Z., Zhao, W., Li, Y., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac710 · Cited by 11
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 13
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 12
Identification of Noncatalytic Lysine Residues from Allosteric Circuits via Covalent Probes
Bongard, J., Lorenz, M., Vetter, I. R., Stege, P., Porfetye, A. T., Schmitz, A. L., Kaschani, F., Wolf, A., Koch, U., Nußbaumer, P., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00101 · Cited by 11
Duchamp, E., & Hanessian, S. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c03085 · Cited by 11
Miura, C., Shindo, N., Okamoto, K., Kuwata, K., & Ojida, A. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00547 · Cited by 12
Serrano-Aparicio, N., Moliner, V., & Świderek, K. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c02614 · Cited by 12
Protein Labeling and Crosslinking by Covalent Aptamers
Tivon, Y., Falcone, G. N., & Deiters, A. (2021) · Angewandte Chemie · doi:10.1002/ange.202101174 · Cited by 11
A patent review of FGFR4 selective inhibition in cancer (2007-2018)
Quintanal-Villalonga, À., Ferrer, I., Molina‐Pinelo, S., & Paz-Ares, L. G. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1624720 · Cited by 11
Jin, Q., Zhang, D., Gao, M. Q., Jiang, C., & Zhang, J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115862 · Cited by 11
A patent review of CYP3A4 inhibitors (2018 – present)
Tu, D., Hu, X., Lei, J.-X., Liu, S., Xiao, Z.-P., Yang, L., & Ge, G. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2470294 · Cited by 10
Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor
Wang, Y., Liu, J., Zhang, Y., Zhao, J., Wang, C. W. C., Cui, H. S., Meng, F., Aliper, A. M., Liang, T., Yan, F., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00928 · Cited by 11
Yuan, B., Ma, M., Wu, Y., Liu, J., Chen, M., Lai, Y., Zhang, S., & Xin, M. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117948 · Cited by 10
Dai, M., Wang, Y.-L., Fan, J. K., Dai, Y., Ji, Y., Sun, Y.-M., Xia, P., Li, L., Wang, Y., Duan, W., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00567-3 · Cited by 10
Kim, H., Byun, D. P., Thakur, K., Ritchie, J., Xie, Y., Holewinski, R. J., Suazo, K. F., Stevens, M., Liechty, H., Tagirasa, R., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00025 · Cited by 10
Janero, D. R., Korde, A., & Makriyannis, A. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.06.022 · Cited by 10
Affinity‐Driven Covalent Modulator of the Glyceraldehyde‐3‐Phosphate Dehydrogenase (GAPDH) Cascade
Chern, J., Lu, C., Fang, Z., Chang, C., Hua, K., Chen, Y., Ng, C. Y., Chen, Y. S., Lam, Y., & Wu, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801618 · Cited by 10
Omer, H. M., Liu, P., & Brummond, K. M. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00788 · Cited by 10
Tabuchi, Y., Watanabe, T., Katsuki, R., Ito, Y., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d1cc01773j · Cited by 10
Quinazolinone-Peptido-Nitrophenyl-Derivatives as Potential Inhibitors of SARS-CoV-2 Main Protease
Giang, H. N. H., Chou, F., Chen, C., Chou, S.-C., Huang, S., Wu, T., Huê, B. T. B., Lin, H., & Wu, T. (2023) · Viruses · doi:10.3390/v15020287 · Cited by 10
Shen, J., Du, W.-W., Xia, Y.-L., Zhang, Z.-B., Yu, Z., Fu, Y., & Liu, S.-Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044237 · Cited by 13
Bajaj, T., Wehri, E., Suryawanshi, R. K., King, E., Pardeshi, K. A., Behrouzi, K., Khodabakhshi, Z., Schulze‐Gahmen, U., Kumar, G. R., Mofrad, M. R. K., et al. (2023) · RSC Advances · doi:10.1039/d3ra01915b · Cited by 10
Impact of the structures of macrocyclic Michael acceptors on covalent proteasome inhibition
Kitahata, S., Yakushiji, F., & Ichikawa, S. (2017) · Chemical Science · doi:10.1039/c7sc02941a · Cited by 10
Dong, J., Su, L., & Liu, G. (2019) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8542 · Cited by 10
Zhang, Z., Nakata, E., Dinh, H., Saimura, M., Rajendran, A., Matsuda, K., & Morii, T. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202103304 · Cited by 10
Gu, T., Cai, J., Auster, A., Torres, E., Zhang, D., Khojasteh, S. C., & Wang, S. (2024) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2024.100027 · Cited by 10
Ouerdani, A., Valenzuela, B., Treijtel, N., Haddish‐Berhane, N., Desphande, S., Srinivasan, S. S., Smith, E., & Ruixo, J. J. P. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04753-0 · Cited by 9
Covalent aptamers: agents with promising therapeutic and diagnostic potential
Albright, S., Boette, J., Cacace, M., & Deiters, A. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00133a · Cited by 9
The covalent docking software landscape: features and applications in drug design
Singh, N., Vayer, P., & Villoutreix, B. O. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf697 · Cited by 10
Kamoshita, S., Matsui, S., Suto, N., & Sakurai, K. (2021) · ChemBioChem · doi:10.1002/cbic.202100388 · Cited by 9
Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase
Prucha, G. R., Henry, S., Hollander, K., Carter, Z. J., Spasov, K. A., Jorgensen, W. L., & Anderson, K. S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115894 · Cited by 9
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.3 · Cited by 10
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707875 · Cited by 10
Jeong, S., Kang, C., Park, S., Ju, S., Yoo, J., Yoon, I., Yun, H., & Jung, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14111092 · Cited by 9
Awoonor‐Williams, E. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp03080b · Cited by 9
Electrophile Scanning Reveals Reactivity Hotspots for the Design of Covalent Peptide Binders
Grob, N. M., Remarcik, C., Rössler, S. L., Wong, J. Y. K., Wang, J. C. K., Tao, J., Smith, C. L., Loas, A., Buchwald, S. L., Eaton, D., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00538 · Cited by 9
Inhibiting sphingosine 1-phosphate lyase: From efficacy to mechanism
George, N., & Xiao, J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106585 · Cited by 10
Bjij, I., Khan, S., Ramharack, P., Cherqaoui, D., & Soliman, M. E. S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28556 · Cited by 9
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond
Serafim, R. A. M., Gehringer, M., & Borsari, C. (2024) · Pharmaceuticals · doi:10.3390/ph17020206 · Cited by 9
Awoonor‐Williams, E., & Abu‐Saleh, A. A. A. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c00310 · Cited by 8
Discovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Quevedo, M. A., & Dehaen, W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00460 · Cited by 8
Cerutti, J. P., Diniz, L. A., Santos, V. C., Larrea, S. C. V., Alonso, G., Ferreira, R. S., Dehaen, W., & Quevedo, M. A. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00631 · Cited by 8
Jaman, S., Tasmi, S. F., Shahriar, I., & Halim, M. A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00508 · Cited by 8
Peptide-Based Targeted Covalent Inhibitors
Cao, F., Guo, R.-C., Zhang, Z., & Yu, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18100 · Cited by 8
Yan, X. H., Qu, C., Li, Q., Zhu, L., Tong, H. H. Y., Liu, H., Ouyang, Q., & Yao, X. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.03.027 · Cited by 8
Detection and Quantification of Drug–Protein Adducts in Human Liver
Zelter, A., Riffle, M. E., Shteynberg, D. D., Zhong, G. G., Riddle, E. B., Hoopmann, M. R., Jaschob, D., Moritz, R. L., Davis, T. N., MacCoss, M. J., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00663 · Cited by 8
Xu, P., Ji, L., Zhan, Y., Ou, Y., Shao, X., Zhuang, X., Hua, F., Li, F., Chen, H., Chu, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202412515 · Cited by 9
Covalent Modification of the JH2 Domain of Janus Kinase 2
Henry, S. P., Liosi, M.-E., Ippolito, J. A., Menges, F., Newton, A. S., Schlessinger, J., & Jorgensen, W. L. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00414 · Cited by 8
Sun, S., Cheng, D., Kong, S., Li, X., Li, T., Yu, Q.-L., & Wang, L. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4703 · Cited by 9
Han, X., Huang, Y., Wei, L., Chen, H., Guo, Y., Tang, Z., Hu, W., Xia, Q., Wang, Q., Yan, J., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115624 · Cited by 8
Measuring and predicting warhead and residue reactivity
Awoonor‐Williams, E., Kennedy, J., & Rowley, C. N. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.09.001 · Cited by 11
Bús, C., Kúsz, N., Kincses, A., Szemerédi, N., Spengler, G., Bakacsy, L., Purger, D., Berkecz, R., Hohmann, J., Hunyadi, A., et al. (2020) · Molecules · doi:10.3390/molecules25245983 · Cited by 9
A targeted covalent small molecule inhibitor of HIV-1 fusion
Zhou, G., He, L., Li, K. H., Pedroso, C. C. S., & Gochin, M. (2021) · Chemical Communications · doi:10.1039/d1cc01013a · Cited by 8
MS methods to study macromolecule-ligand interaction: Applications in drug discovery
Sirtori, F. R., Altomare, A., Carini, M., Aldini, G., & Regazzoni, L. (2018) · Methods · doi:10.1016/j.ymeth.2018.06.005 · Cited by 8
A Mechanism-Based Sphingosine-1-phosphate Lyase Inhibitor
Pons, G., Riba-López, D., Casasampere, M., Izquierdo‐García, E., Abad, J. L., Fabriàs, G., Ortega, P. G. R., González, J. J. L., Montejo, M., Casas, J., et al. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b02420 · Cited by 8
Proximity-induced amino-yne reaction for selective MDM4 conjugation via propargylated sulfonium
Lian, C., Li, Y., Hou, Z., Zhong, W., Tian, Y., Yin, F., Li, Z., Zhou, D., & Wang, R. Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.04.015 · Cited by 8
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 9
Basu, R., & Fletcher, S. (2026) · RSC Chemical Biology · doi:10.1039/d5cb00230c · Cited by 7
Wang, S., Wang, L., Hadisurya, M., Nia, S. S., Tao, W. A., Dykhuizen, E. C., & Krusemark, C. J. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202516630 · Cited by 8
Tillmanns, J., Kicuntod, J., Lösing, J., & Marschall, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052823 · Cited by 7
Harrison, K., Carlos, P. W., Ullrich, S., Aggarwal, A., Johansen‐Leete, J., Sasi, V. M., Barter, I. K., Maxwell, J. W. C., Bedding, M. J., Larance, M., et al. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202401606 · Cited by 7
Dynamics Playing a Key Role in the Covalent Binding of Inhibitors to Focal Adhesion Kinase
Liu, Y., Tan, J., Hu, S., Hussain, M., Qiao, C., Tu, Y., Lu, X., & Zhou, Y. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00418 · Cited by 7
Agarkov, A. S., Mingazhetdinova, D. O., Nefedova, A. A., Gabitova, E. R., Ovsyannikov, A. S., Litvinov, I. А., Islamov, D. R., Дороватовский, П. В., Solovieva, S. Е., & Antipin, I. S. (2024) · Russian Chemical Bulletin · doi:10.1007/s11172-024-4359-7 · Cited by 8
Tasdan, Y., Balaji, G. R., Akhtar, N., Ilyichova, O. V., Cunliffe, T., Heras, B., Strat, L. L., Murray, J. B., Capuano, B., Scanlon, M. J., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00016 · Cited by 7
Du, J., Li, S., Xu, F., Lin, Z., Hong, T., Li, Y.-F., Deng, Z., Tan, Y., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00229 · Cited by 7
Wang, L., Riel, L. P., Bajrami, B., Deng, B., Howell, A. R., & Yao, X. (2020) · ChemBioChem · doi:10.1002/cbic.202000605 · Cited by 10
Serendipitous Identification of a Covalent Activator of Liver Pyruvate Kinase
Battisti, U. M., Gao, C., Nilsson, O., Akladios, F. N., Lulla, A., Bogucka, A., Nain‐Perez, A., Håversen, L., Kim, W., Borén, J., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200339 · Cited by 7
Measurement and utilization of the proteomic reactivity by mass spectrometry
Punzalan, C., Wang, L., Bajrami, B., & Yao, X. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21837 · Cited by 8
Graph neural networks for identifying protein-reactive compounds
Gil, V., & Rowley, C. N. (2024) · Digital Discovery · doi:10.1039/d4dd00038b · Cited by 9
Adeniji, E. A., Olotu, F. A., & Soliman, M. E. S. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666180718110231 · Cited by 7
Jiang, Q.-L., Zhu, Z., Shou, P., Teng, F., Zhu, Y., Zhao, H., & Yang, B. (2019) · Phytochemical Analysis · doi:10.1002/pca.2898 · Cited by 7
Synthesis and Biological Evaluations of Electrophilic Steroids Inspired by the Taccalonolides
Clanton, N. A., Hastings, S. D., Foultz, G. B., Contreras, J. A., Yee, S. S., Arman, H. D., Risinger, A. L., & Frantz, D. E. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00534 · Cited by 7
Fındık, V., Ruiz‐López, M. F., & Erdem, S. S. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob01963e · Cited by 7
Bush, J. T., Leśniak, R. K., Yeh, T.-L., Belle, R., Kramer, H., Tumber, A., Chowdhury, R., Flashman, E., Mecinović, J., & Schofield, C. J. (2018) · Chemical Communications · doi:10.1039/c8cc07706a · Cited by 7
Prediction of Drug Clearance from Enzyme and Transporter Kinetics
Kulkarni, P., Youssef, A. S., & Argikar, A. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_14 · Cited by 7
Crystal structure of human 17beta-HSD type 1 in ternary complex with PBRM and NADP+
Li, T., & Lin, S. X. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6cge/pdb · Cited by 7
Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer
Yong, W. P., Zhang, S., Zhang, Z., Li, Z., Qin, Y., Qi, X., Wang, D., Zhang, Y., Li, J., Liu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01515 · Cited by 7
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108187 · Cited by 6
Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells
Junior, J. C. Q., Rocho, F. D. R., Montanari, A., Leitão, A., Mignone, V. W., Arruda, M. A., Turyanska, L., & Bradshaw, T. D. (2019) · RSC Advances · doi:10.1039/c9ra07161j · Cited by 6
Classifying covalent protein binders by their targeted binding site
Bedewy, W. A., Mulawka, J. W., & Adler, M. J. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130067 · Cited by 6
Zhang, Q., Hu, Z.-L., Shen, Q., Chen, Y., & Lu, W. P. (2017) · Molecules · doi:10.3390/molecules22050788 · Cited by 6
Novel advances in biotransformation and bioactivation research—2019 year in review
Khojasteh, S. C., Driscoll, J. P., Jackson, K. D., Miller, G. P., Mitra, K., Rietjens, I. M. C. M., & Zhang, D. (2020) · Drug Metabolism Reviews · doi:10.1080/03602532.2020.1772281 · Cited by 6
Targeted Covalent Inhibitors for the Treatment of Malaria?
Kulkarni, S., Urbahns, K., & Spangenberg, T. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00684 · Cited by 6
Yang, Z. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2263 · Cited by 6
A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease
Cheng, Y., Wu, J., Han, Y., Xu, J., Da, Y., Zhao, Q., Guo, G., Zhou, Y., Chen, Y., Liu, J., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116219 · Cited by 6
Suto, N., Kamoshita, S., Hosoya, S., & Sakurai, K. (2021) · Angewandte Chemie · doi:10.1002/ange.202104347 · Cited by 6
Thiol Reactivity of N-Aryl α-Methylene-γ-lactams: Influence of the Guaianolide Structure
Dempe, D. P., Ji, C., Liu, P., & Brummond, K. M. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01530 · Cited by 7
Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
Shunmugam, L., Ramharack, P., & Soliman, M. E. S. (2017) · The Protein Journal · doi:10.1007/s10930-017-9736-8 · Cited by 6
Torres‐Gómez, H., Keiff, F., Hortschansky, P., Bernal, F. A., Kerndl, V., Meyer, F., Messerschmidt, N. B., Molin, M. D., Krüger, T., Rybniker, J., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116849 · Cited by 5
Development of an Irreversible Peptidomimetic Radioligand for PET Imaging of ST14 Protease
Peng, T., Huang, G., Zhao, H., & Liu, J. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00564 · Cited by 5
Kinetic Modeling of Covalent Inhibition: Effects of Rapidly Fluctuating Intermediate States
Ghaby, K., & Roux, B. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00952 · Cited by 5
Ragheb, M. A., Salem, M. E., Ali, M. M., Abdelhamid, I. A., Raza, N., & Soliman, M. H. (2025) · ACS Omega · doi:10.1021/acsomega.5c06977 · Cited by 11
Relationship among structure, cytotoxicity, and Michael acceptor reactivity of quinocidin
Nakagawa, Y., Sawaki, Y., Miyanishi, W., Shimomura, S., Shibata, T., & Ojika, M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115308 · Cited by 5
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.